Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

NCT06673134 · tracked via the Priya Life Science China tracker

Sponsor

Tongji Hospital

Phase

Observational

Started

2023-12-01

Last updated

2025-09-04

Condition(s) studied

Crohn Disease

Investigational drug(s) / intervention(s)

enteral nutritionImmunotherapybiological agentsGlucocorticoidsfecal microbiota transplantation

enteral nutrition: exclusive enteral nutrition therapy or Partial enteral nutrition

Immunotherapy: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc

biological agents: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc

Glucocorticoids: Glucocorticoids treatments are given

fecal microbiota transplantation: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc

Study summary

To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same treatment options; (3) Clinical outcome;

Eligibility

Sex

ALL

Min age

1 Month

Max age

16 Years

Healthy volunteers

Inclusion Criteria: * Children under 17 years old; * Children with a definite diagnosis of Crohn's disease; * Patients and their guardians must sign informed consent; Exclusion Criteria: * Other conditions deemed inappropriate by the doctor to participate in the study;

Primary outcome measure(s)

To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings — 14 weeks
14 weeks clinical response rate.

Trial sites (1)

Facility	City	Region	Status
Tongji Hospital, Wuhan, 430030	Wuhan	China

More Tongji Hospital trials in China

Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR Starting soon

A Study on the Efficacy and Safety of Endoscopic Ultrasound-guided Gastro-/Duodeno-cholecystostomy for the Treatment of Gallstones. Enrolling by invitation

Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis Starting soon

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD Recruiting

Denosumab Strategy for Liver Cancer With Bone Metastases Starting soon

Other trials for the same condition

Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Recruiting

Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression Recruiting

Specific Dietary Pattern for Crohn's Disease Patients Following Surgery Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06673134 on ClinicalTrials.gov ↗ ← All trials in China